Provided is a use of the human gene LIM domain only 4 (lmo4) for preparation of external therapeutic drugs of psoriasis. The active components of the drugs are the recombinant lentivirus vectors for inhibiting gene lmo4 expression or the recombinant lentiviruses for inhibiting gene lmo4 expression.
展开▼